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Abstract
Clostridium difficile has been recognized as a pathogen in humans for over 40 years, but in the past
decade the incidence has increased and, more importantly, the clinical presentation and
consequences have become more serious, with increased morbidity and mortality. The emergence
of a new, more pathogenic strain, BI/NAP1/027, has driven these shifts. Treatment of this disease has
been with two antibiotics, metronidazole and vancomycin, but increasing recurrence, not uncommon
with C. difficile infections, has prompted research into several alternative therapies. These include
a new class of antibiotic (fidaxomicin), a monoclonal antibody, a vaccine, and most recently
a biotherapeutic (which, in this case, is a nontoxin-producing strain of C. difficile). The future
management of C. difficile infection will probably require a combination of these approaches once we
have the data from ongoing studies.
Introduction
It is clear that Clostridium difficile is gaining ground on us.
New virulent strains are harder to remove by cleaning
the environment and more deadly once they infect the
patient. Data from 2006 by Henrich et al. [1] showed the
crude mortality rate in the US to be 10.1%, which was
even higher in those over 70 years of age, at 15.4%. No
large studies of mortality have been published based on
data from the past 3 years. Coupled with the reduced
effectiveness of first-line therapy, it is clear that we need
to adopt new approaches to treatment to keep it at bay.
Thankfully, several new approaches havebeen developed
and are in clinical trials.
C. difficile was first described as a human pathogen
in 1978 as a cause of antibiotic-associated diarrhea or
colitis. This condition was usually associated with
courses of antibiotics, namely clindamycin or cephalos-
porins, which severely disrupt the normally protective
bowel flora and thus enable C. difficile to adhere and
produce toxins that lead to an inflammatory response
and gastrointestinal disease. The condition also tended
to be limited to the hospital setting. For approximately
30 years the disease was a significant cause of death in
the elderly. However, in the past 5–10 years the organism
has evolved to become more virulent (acquired from
multiple sources), more antibiotic resistant, and infec-
tious to new types of patients. A new hypervirulent
epidemic strain has also emerged in the US and Europe,
which presents major clinical problems for infection
control as it leads to higher rates of disease recurrence
and thus environmental contamination.
We will discuss the changing epidemiology in terms
of which patients are now being infected, the possible
sources they may have been colonized from, the emerging
types of C. difficile and their virulence (or capacity to
cause disease), and the mortality-related and financial
impacts on the healthcare system. We will also examine
the management options of C. difficile infection and
the relative strengths and weaknesses of current and
future potential agents. Future agents encompass new
antibiotics, monoclonal antibodies, vaccines, and
biotherapeutics.
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C. difficile accounts for 20–30% of cases of antibiotic-
associated diarrhea and is the number one cause of
hospital-associated diarrhea in healthcare settings
including long-term nursing facilities. However, estab-
lishing an absolute incidence of the disease in the US is
not possible as C. difficile infection is not a reportable
disease (although there are individual states, such as
Ohio, where it is).
The situations are clearer in Canada and Europe where
surveillance mechanisms exist; indeed, the emergence of
anepidemic ofC.difficile was initiallyreported inQuebec,
Canada by Pépin et al. in 2004 [2]. These authors were the
first to report an almost fivefold increase in cases of
C. difficile infection over a 13-year period, increasing
from 35.6 cases per 100,000 population in 1991 to 156.3
cases per 100,000 population in 2003 [2]. Strikingly, the
proportion of severe or complicated C. difficile infections
also more than doubled in this period. A similar epide-
miological picture emerged from Pittsburgh, USA, with
more cases of C. difficile infection being reported from
other US sites, and data from the National Hospital
Discharge Survey encompassing 500 hospitals showed a
doubling of discharges listing C. difficile infection as the
cause of hospitalization.
It transpired that the main reason for this increase in
cases of C. difficile infection was the emergence of a new
strain, which has been termed BI/NAP1/027 (or just
ribotype 027). The BI/NAP1/027 name is based on three
different molecular or biochemical typing methods used
to differentiate strains of bacteria [3]. Because of the
confusion surrounding these three terms, the ribotyping
system is the preferred method, thus in North America
the epidemic strain is known as the 027 ribotype. This
strain has now been reported in at least 40 US states so it
is reasonable to assume it is distributed nationally [4].
In the UK, a sustained and high-profile outbreak of
C. difficile infection leading to multiple deaths led to
government intervention mandating total surveillance
and reporting of all cases of C. difficile infection to the
central health authority. Again, the 027 ribotype was the
most common, but types 106 and 001 were also not
uncommon in England. There was a quadrupling of death
certificates where C. difficile infection was mentioned in
England and Wales over the period 2004–2007 but this
was followed by a 29% decrease in 2008 [5] after the
institution of strict infection control policies and other
mechanisms.
An excellent review by Freeman et al. [6] describes in
detail the epidemiology of C. difficile infection in Europe,
North America, and other parts of the world. Clearly the
rapid spread of the 027 ribotype has caused significant
alarm in the infection control community leading
to Clements et al. [7] analyzing the risks of further
worldwide spread of this strain. Until 2007, this strain
was not reported outside Europe and North America, but
a survey of the period 2008–2010 showed interconti-
nental spread had occurred. The question was, how?
The movementofpeople,animals, vectors, and inanimate
objects across international borders has spread many
infectious diseases, including influenza, acute respiratory
distress syndrome, malaria, and others. The issues of
identifying carriers of C. difficile strains, especially 027,
are impossible as carriers are not screened. Clearly, an
asymptomatic carrier can move between countries and
healthcare systems and be the source of an outbreak. The
contamination of foodstuffs and the carriage and infec-
tion of animals, including domestic pets and livestock
(suchasdogs,horsesandpigs),hasalsobeenreported[8].
It would appear an almost impossible task to prevent 027
and other strains of C. difficile moving between countries,
so reducing the risks of C. difficile infection in high-risk
patients becomes a priority.
Prior to 2000, C. difficile infection was almost exclusively
found in the hospital setting among older adults.
However, as the new strain has emerged, C. difficile has
been reported to be a cause of community-acquired
infection among a wider age range of patients, including
children. Indeed it was long thought that children under
1 year of age could not contract C. difficile, possibly due
to the lack of toxin receptors in their colon compared
with adults. Recently, Zilberberg et al. [9] examined two
large national US databases in an effort to determine the
incidence of C. difficile infection among children over the
period 1997–2006. These large databases showed a
marked increase in rate of pediatric C. difficile infection-
related hospitalizations from 7.24 to 12.80 per 10,000,
with most of the increase occurring between 2000 and
2006. Children aged 1–4 years were the most likely to
have the disease, while newborns were the least likely.
There were no differences in incidence between gender
and races.
This new strain of C. difficile has incurred a significant
financial impact as well as increasing the morbidity and
mortality burden. Historically, the attributed mortality
to C. difficile infection was less than 2% but this has
increased to over 10% in recent years [1]. Additionally,
the excess costs of C. difficile infection have been
estimated to be more than 55,000 inpatient days and
over $55 million annually in the state of Massachusetts.
Extrapolating from this, the estimated annual excess
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$3.2 billion per year [10]. As the number of cases has
increased since this estimate, it is clear that C. difficile
infection is a major healthcare burden in need of urgent
and appropriate management.
Virulence
So why has this disease altered over the past decade? The
picture is complex and is only just coming into focus.
There have also been some controversies along the way.
C. difficile produces two toxins that have been shown to
cause disease in humans, toxin A and toxin B, although
there has been much recent controversy as to the relative
role of the two proteins. Lyras et al. [11] reported that only
toxinB,nottoxinA,wasessentialforvirulenceanddisease.
However, Kuehne et al. [12] subsequently demonstrated
that this was not the case by constructing gene-knockout
mutant strains of C. difficile. Strains producing either toxin
A or toxin B alone both caused disease, and those lacking
the ability to produce both toxins completely lacked
virulence, providing evidence that both toxins play a part
in the disease and must be considered equally in the
development of diagnostic tests for C. difficile.
Adding to the complexity of the evolving C. difficile story,
Merrigan et al. [13] recently described phase-dependent
hyperproduction of the two toxins and, perhaps more
intriguingly, increased production of spores by the
027 hypervirulent strain. In the exponential growth
phase, both hypervirulent and nonhypervirulent strains
producedlow levels of toxin A and toxin B, but in contrast
to previous reports that tested toxin levels at a different
growth phase, the levels of toxin were below the
detectable thresholds. During the stationary phase of
growth, however, hypervirulent isolates produced ele-
vated levels of toxin. More significantly though, they
produced more spores, and did so earlier, than all other
isolates. The authors postulated that increased sporula-
tion, potentially in synergy with elevated toxin produc-
tion, may contribute to the widespread disease now
associated with hypervirulent C. difficile strains such as the
027 ribotype. Another factor was identified by studies of
the role of S-layer proteins in the cell wall when it was
shown that the outer coat of C. difficile may also play
a role in increasing the adhesion of the organism to
various surfaces, including the gastrointestinal lining and
perhaps inanimate surfaces, thus making spore removal
more difficult (G. Vedantam, personal communication).
Indeed, Dang et al. [14] have recently explored these
S-layer proteins as possible novel drug targets.
Current management of C. difficile infection
Since the original description of C. difficile infection
in 1978, two antibiotics have been the mainstay of
treatment: metronidazole and oral vancomycin (only the
latter is approved by the US Food and Drug Adminis-
tration). Because of the relative impact of the disease,
there was little concerted effort to develop new agents
until the emergence of reduced susceptibility to metro-
nidazole and the more recent occurrence of 027 and
other hypervirulent strains, which led to a renewed effort
to develop more effective drugs.
The recent Society for Healthcare Epidemiology of
America (SHEA) and the Infectious Diseases Society
of America (IDSA) guidelines for the management of
C. difficile infection make recommendations for the
selection of drugs; notably, the most important action
before initiating any specific antibiotic therapy is the
cessation of the inciting antimicrobial as soon as possible
[15]. The next step is to determine whether the infection is
severe, characterized by a white blood cell count or a
serum creatinine level that is 1.5 times greater than the
premorbid level. If neither of these parameters is present,
then the patient is deemed to have mild to moderate
infection and warrants the first line of defense, metroni-
dazole. However, if the patient is deemed to have
severe C. difficile infection based on either of the above
two parameters and their general clinical condition, then
vancomycin, the second line of defense, is recommended.
Presently, most patients (75%) are treated initially with
metronidazole, but the rate of recurrence tends to be
25–30% or higher depending on underlying disease and
other factors. Indeed, resistance to this drug has been
increasingly reported in various parts of the world, with
Spain reporting rates of 6.3–7.7% resistance to metroni-
dazole in the early part of this century; however, this
could not be confirmed in other laboratories. In the UK,
24.4% of C. difficile strains were reported as having a
reduced susceptibility to metronidazole, but were not
resistant. The exact mechanism of this reduced suscept-
ibility is not fully understood.
The relative merit of these two antibiotics has been the
subject of some debate. Recent studies have compared
metronidazole and vancomycin in terms of clinical cure
and recurrence 30 days post-therapy. Zar et al. [16]
stratified patients using a novel severity scoring system
into mild or severe infection prior to randomly assigning
patients to receive either metronidazole or vancomycin
for 10 days. In the mildly infected cohort there was no
difference between cure rates with the two regimens
(90% metronidazole versus 98% vancomycin), while
in the severely ill group the cure rates were 76% for
metronidazole and 97% for vancomycin (p =0 . 0 2 ) .
There was no statistically significant difference in the
recurrence rates.
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randomized comparative studies of a toxin binder,
tolevamer, and metronidazole and vancomycin, which
showed vancomycin to be superior to metronidazole in
severely ill patients, but with negligible differences in
the mild or moderately sick C. difficile infection patients
(Table 1). Confusingly, a second similar tolevamer trial
in Europe failed to show any difference between
metronidazole and vancomycin, even in the treatment
of severe C. difficile infection. Incidentally, tolevamer was
not shown to be effective in treating C. difficile infection
either, and development was discontinued.
Oral vancomycin would probably be used more fre-
quently in treating C. difficile if not for concerns that
potentiallydifficult-to-treatpathogenssuchasmethicillin-
resistant Staphylococcus aureus (MRSA),
and E.faecium might develop vancomycin resistance.
Recent data from Miller et al. [18] examined four different
time periods at the same hospital at which the antibio-
tic usage and the incidence of C. difficile infection and
vancomycin-resistant enterococci were compared. In the
first period, metronidazole was used as the first line of
defense before there had been outbreak of ribotype 027
C. difficile infection, in the second period, metronidazole
was again the first-line agent but was administered during
the 027 C. difficile infection outbreak, in the third period,
vancomcyinwasusedasthefirst-linetherapyforC.difficile
infection, and the last period to be assessed reverted to
metronidazole. They concluded that there was no link
between the specific agent for the treatment of C. difficile
infection and vancomycin-resistant enterococci coloniza-
tion among hospitalized patients. Moreover, they showed
that preferential use of oral vancomycin did not result
in an increase in the numbers of vancomycin-resistant
enterococci cases.
Overall, the clinical data from several recent studies
support the use of vancomycin in severe C. difficile
infection cases and dispel the concerns of vancomycin-
resistant enterococci selection. In view of the diminishing
efficacy of metronidazole described by Gerding [19], it
may be reasonable to use vancomycin earlier in some
patients to avoid some of the treatment failures seen with
metronidazole.
Future C. difficile therapies
With first-line therapy beginning to fail, it is clear that
new approaches are needed. As one might expect, several
of these new approaches are targeted at those most
at risk. It is well known that some patients, especially
the elderly and/or those who have been exposed to
antibiotics, do not mount a robust immune response to
C. difficile and are particularly vulnerable to recurrent or
severe disease. Consequently, ways to boost the immune
system, such as with a vaccine or antibody enhancement
or modification of the host gut flora, are being
investigated. Also under development is a novel anti-
biotic, fidaxomicin.
Fidaxomicin is a macrocyclic antibiotic with a narrow
spectrum of antibacterial activity, in that it acts only
against certainGram-positivespeciesandappearstohave
minimal activity against other members of the bowel
flora. It has been shown to be safe in two large phase III
clinical trials involving more than 1,100 patients. Recent
presentations have shown fidaxomicin to be equal to
vancomycin in terms of clinical cure rate but superior in
terms of lower recurrence rates and global clinical cure
rates (i.e., clinical cure rates combined with recurrence
rates) (see Figure 1). The pooled data from the two
studies (which were conducted in North America and
Europe) were analyzed to elucidate the efficacy of the
two drugs among the epidemic BI/NAP1/027 strains
and the nonepidemic isolates [20].
Recurrence rates were similar for the two drugs in patients
infected with the epidemic isolates, although the rate
was lower for fidaxomicin (23.3% versus 31.2% for
vancomycin), whereas analysis of recurrence in the non-
epidemic-infected patients revealed that fidaxomicin was
superior to vancomycin (8.4% versus 25.3%; p <0 . 0 0 3 ) .
The cure rates in the epidemic- and nonepidemic-infected
patients treated with vancomycin or fidaxomicin were
notstatisticallydifferentfromeachother,butcureratesfor
the 027 strain were significantly lower than for non-
epidemic strains for both vancomycin (p
fidaxomicin (p < 0.009) [20]. Fidaxomicin is currently
under review by the regulatory authorities in the US and
Europe.
It will be interesting to see the reaction of the normally
cautious infectious disease community to this new agent,
which, according to the two controlled studies, displays
similar clinical cure rates to vancomycin but a superior
Table 1. Clinical cure rates from a phase III randomized
comparative trial of tolevamer, vancomycin, and metronidazole




Mild 45 (59.2%) 23 (85.2%) 26 (78.8%)
Moderate 44 (46.3%) 58 (79.5%) 40 (75.5%)
Severe 35 (36.8%) 28 (84.8%)* 37 (64.9%)*
*p = 0.04.
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Enterococcus faecalis,,
< 0.022) andrate in terms of preventing recurrences (and global
clinical cure rates), which occur in almost a quarter of all
C. difficile infection cases and even more often in the
sicker patients.
Immunological approaches are being developed by
two other companies, one of which is Merck, who are
developing the use of monoclonal antibodies directed
against the two toxins A and B. Lowy et al. [21] reported
a phase II double-blind placebo-controlled trial of the
efficacy of CDA1 plus CDB1 involving 200 patients, 101
in the antibody group and 99 in the placebo cohort.
Patients received either metronidazole or vancomycin
for treatment of their C. difficile infection, chosen by the
local physician. Patients were randomly assigned to
receive either a single intravenous infusion of 10 mg each
of CDA1 and CDB1 per kg body weight or a placebo. The
patients were then followed for 84 days, during which
they monitored stool frequency, consistency, and other
relevant parameters. The primary endpoint was the
recurrence of C. difficile infection; the secondary end-
points included number of days until the resolution of
the initial episode, severity of the initial episode, and
failure of antibiotic treatment. Levels of serum anti-
bodies against toxins A and B were measured in all
patients. The initial results look promising. The rate of
recurrence of C. difficile infection was lower among those
who received the monoclonal antibodies, 7% versus
25%, (95% confidence interval 7–29; p < 0.001). The
recurrence rates among those infected with the epidemic
strain were 8% in the antibody cohort and 32% in the
placebo group (p = 0.06). In patients having more than
one prior infection the recurrence rates were 7% and
38% for the antibody and placebo groups, respectively
(p = 0.006). There were also fewer adverse events in
the antibody group: 18 versus 28 (p = 0.09).
An alternative immunologic approach to managing
C. difficile infection is the use of a vaccine; consequently,
Sanofi-Aventis are currently developing the ACAM-
CDIFF™ for this purpose. Data presented by Foglia [22]
showed that the initial intramuscular-delivered vaccine
directed towards both toxin A and B was well tolerated in
200 subjects in six phase I studies. The vaccine success-
fully induced IgG against toxin A and B in most subjects
but the response rate was lower in those aged over
70 years compared with those aged 25 years. Preliminary
data in three patients with recurrent C. difficile infection
were promising but it is too early to determine the exact
role of vaccine therapy in managing this aspect of the
disease.
The most recent development in managing C. difficile
infection has been a phase I trial on a biotherapeutic:
nontoxigenic C. difficile (NTCD) [23]. NTCD is a strain of
C. difficile that does not produce toxins but attaches itself
to the usual bowel receptors thereby denying access to the
pathogenic variety of C. difficile and thus preventing it
from producing toxins. Phase I data showed that NTCD
colonized the stools of normal subjects following
vancomycin treatment. The administration of this novel
agent was well tolerated and persistence of the clostridial
Figure 1. Comparison of clinical cure, recurrence, and global cure
rates (%) of fidaxomicin (FID) and vancomycin (VAN) in patients
with Clostridium difficile [20]
p < 0.003.
Page 5 of 7
(page number not for citation purposes)
F1000 Medicine Reports 2011, 3:6 http://f1000.com/reports/m/3/6spores was seen for over 28 days. Phase II studies, initially
testing NTCD as a recurrence preventative regimen, will
commence in 2011. This approach raises a totally new
approach to managing infections by manipulating the
human microbiome, a new sphere of microbiology based
on 16s RNA analysis of samples of the gastrointestinal
tract, oral cavity, and other anatomical areas in which the
disruption of the normal flora leads to ingress by other
species, which then leads to disease.
Summary and speculation
C. difficile is an evolving organism and with these changes
our ability to recognize the disease and manage it is also
shifting. Previously, two drugs provided an adequate
therapy, but emerging clinical failure of metronidazole,
increasing recurrence rates, associated higher mortality,
and emergent hypervirulent strains with a heightened
ability to persevere in the environment necessitate
new therapeutic approaches. Presently, the use of a new
antibiotic, perhaps in combination with both an immu-
nological and “biotherapeutic” modality, can help not
only the treatment of C. difficile infection but also reduce
the incidence ofthe disease andits impact onhuman lives
and economics.
Abbreviation
NTCD, nontoxigenic C. difficile.
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